Dashboard
Manage Tickers

KZR


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jefferies-downgrades-kezar-life-sciences-to-hold-lowers-price-target-to-7
Jefferies Downgrades Kezar Life Sciences t...
10/17/2025 19:08:03

Jefferies analyst Maury Raycroft downgrades Kezar Life Sciences (NASDAQ:KZR) from Buy to Hold and lowers the price target fr...

kezar-launches-strategic-review-as-fda-roadblock-derails-liver-drug-plans
Kezar Launches Strategic Review As FDA Roa...
10/17/2025 18:38:05

Kezar Life Sciences faces FDA delays for AIH drug trials, implements restructuring, and explores strategic alternatives amid po...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
10/17/2025 17:05:58

this-booz-allen-hamilton-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-friday
This Booz Allen Hamilton Analyst Is No Lon...
10/17/2025 16:23:02

william-blair-downgrades-kezar-life-sciences-to-market-perform
William Blair Downgrades Kezar Life Scienc...
10/17/2025 14:22:55

William Blair analyst Matt Phipps downgrades Kezar Life Sciences (NASDAQ:KZR) from Outperform to Market Perform.

wells-fargo-maintains-equal-weight-on-kezar-life-sciences-lowers-price-target-to-5
Wells Fargo Maintains Equal-Weight on Keza...
10/17/2025 13:01:02

Wells Fargo analyst Derek Archila maintains Kezar Life Sciences (NASDAQ:KZR) with a Equal-Weight and lowers the price target...

Core News & Articles
12 Health Care Stocks Moving In Friday's P...
10/17/2025 12:13:10

why-csx-shares-are-trading-higher-by-over-4-here-are-20-stocks-moving-premarket
Why CSX Shares Are Trading Higher By Over ...
10/17/2025 09:55:54

Core News & Articles
12 Health Care Stocks Moving In Thursday's...
10/16/2025 21:06:04

kezar-life-sciences-initiates-strategic-alternatives-review-announces-workforce-restructuring-and-rights-plan-extension-after-fda-blocks-path-forward-for-zetomipzomib-in-autoimmune-hepatitis-reports-902m-cash-balance
Kezar Life Sciences Initiates Strategic Al...
10/16/2025 20:09:33

Kezar Life Sciences, Inc. (NASDAQ:KZR, the Company))), a clinical-stage biotechnology company developing novel small molecule t...

kezar-life-sciences-q2-eps-187-beats-239-estimate
Kezar Life Sciences Q2 EPS $(1.87) Beats $...
08/13/2025 20:04:50

fda-lifts-pause-on-kezars-liver-drug-trialnext-stop-lupus-study
FDA Lifts Pause On Kezar's Liver Drug Tria...
07/16/2025 15:54:15

Kezar Life Sciences' zetomipzomib trial in autoimmune hepatitis resumes as FDA lifts partial hold following a favorable saf...

hc-wainwright--co-reiterates-neutral-on-kezar-life-sciencesto-neutral
HC Wainwright & Co. Reiterates Neutral on ...
07/16/2025 11:28:00

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Kezar Life Sciences (NASDAQ:KZR) from Neutral to Neutral.

kezar-life-sciences-plans-to-request-fda-lift-clinical-hold-on-zetomipzomib-in-lupus-nephritis-following-idmc-review
Kezar Life Sciences Plans To Request FDA L...
07/15/2025 20:43:06

Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Inde...

kezar-life-sciences-announces-fda-lifted-partial-clinical-hold-on-phase-2a-trial-of-zetomipzomib-for-autoimmune-hepatitis
Kezar Life Sciences Announces FDA Lifted P...
07/15/2025 20:41:54

Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to ...

kezar-life-sciences-q1-eps-227-beats-261-estimate
Kezar Life Sciences Q1 EPS $(2.27) Beats $...
05/14/2025 05:37:56

Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(...

kezar-life-sciences-touts-positive-data-from-mid-stage-study-for-chronic-liver-disease-drug-candidate
Kezar Life Sciences Touts Positive Data Fr...
03/25/2025 14:39:45

Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and ...

kezar-life-sciences-q4-2024-gaap-eps-277-beats-288-estimate-cash-132m
Kezar Life Sciences Q4 2024 GAAP EPS $(2.7...
03/25/2025 11:55:03

Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(2.77) per share which beat the analyst consensus estimate of $(...

kezar-life-sciences-provides-topline-results-from-the-portola-phase-2a-trial-evaluating-zetomipzomib-for-the-treatment-of-patients-with-autoimmune-hepatitis
Kezar Life Sciences Provides Topline Resul...
03/25/2025 11:52:55

Company-hosted conference call and webcast to be held today at 8:00 a.m. ETZetomipzomib treatment results in steroid-sparing bi...

kezar-life-sciences-to-present-topline-results-from-the-portola-phase-2a-trial-evaluating-zetomipzomib-for-the-treatment-of-patients-with-autoimmune-hepatitis-on-tuesday-march-25-2025
Kezar Life Sciences To Present Topline Res...
03/24/2025 12:14:55

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION